Collegium Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Collegium Pharma (COLL) Misses Q1 EPS by $1.29
May 10, 2022 5:04 PM EDTCollegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.39), $1.29 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $78.88 million.
GUIDANCE:
Collegium Pharma sees FY2022 revenue of $450-465 million.
For earnings history and earnings-related data on Collegium Pharma (COLL) click here.
... More